Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease

NCT01690390 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT01690390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01690390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2012
Completion date
July 31, 2016
Enrollment
180 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc